# Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

> **NCT02158520** · PHASE2 · COMPLETED · sponsor: **Academic and Community Cancer Research United** · enrollment: 24 (actual)

## Conditions studied

- Metastatic Melanoma
- Mucosal Melanoma
- Stage IV Cutaneous Melanoma AJCC v6 and v7
- Stage IV Uveal Melanoma AJCC v7
- Unresectable Melanoma

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **BIOLOGICAL:** Ipilimumab
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Nab-paclitaxel
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02158520
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-18
- **Primary completion:** 2017-05-24
- **Final completion:** 2019-10-30
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02158520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02158520, "Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02158520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*